Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (4)
  • Immunotherapy  (2)
  • Erythrocytes  (1)
  • Key words 5-Fluorouracil-induced diarrhea  (1)
Source
Material
Years
Year
Keywords
  • 1
    Electronic Resource
    Electronic Resource
    Possible occurrence of amitotic cell division during haemopoiesis in the Urodeles (1995)
    Springer
    Comparative clinical pathology 5 (1995), S. 183-188 
    Details
    ISSN: 1433-2981
    Keywords: Amitosis ; Haemopoiesis ; Liver ; Urodeles ; Morpho-cytochemistry ; Erythrocytes
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The liver haemopoietic activity of three species of Urodeles (Triturus carnifex, Triturus alpestris and Speleomantes ambrosii) was examined by morphocytochemical approaches (light and electron microscopy, anti-BrdU immunocytochemistry, flow cytometry). The proliferation of haemopoietic cells, detected by the anti-BrdU labelling index, was accompanied by absence of mitotic cell division and the appearance of cells showing features of amitosis (e.g. nuclear constrictions with bundles of electron-dense chromatin) sometime positive to the anti-BrdU immuno-gold reaction. The possible unbalanced segregation of chromatin during the direct division of the nucleus was detected by flow cytometric measurement in terms of heterogeneous relative DNA content in peripheral blood cells. The presence in the bloodstream samples of cells (erythrocytes) with replicating DNA, nuclear constrictions and binucleations is also consistent with a situation of direct nuclear division.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00368042
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour (1995)
    Springer
    Supportive care in cancer 3 (1995), S. 194-197 
    Details
    ISSN: 1433-7339
    Keywords: Immunotherapy ; Interleukin-2 ; Melatonin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Recent advances in our knowledge of psychoneuroimmune interactions involved in the control of tumour growth have shown the possibility of manipulating host anticancer defences through a neuroimmunotherapeutic strategy. In particular, our previous studies have demonstrated that the concomitant administration of the pineal neurohormone melatonin may amplify the antitumour efficacy of interleukin-2 (IL-2) in humans. On this basis, a study was planned to investigate the influence of neuroimmunotherapy with low-dose IL-2 plus melatonin on survival time and on performance status in untreatable metastatic cancer patients. The study included 100 patients with metastatic solid tumours, for whom no standard therapy was available. They were randomized to receive IL-2 (3 x 106 IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally) or supportive care alone. Partial tumour regressions were seen in 9/52 (17%) patients treated with the immunotherapy, and in none of the patients treated with supportive care alone. The percentage of survival at 1 year was significantly higher in patients treated with IL-2 and melatonin than in those receiving the supportive care alone (21/52 versus 5/48, P〈0.005). Moreover, the performence status improved in 22/52 patients of the immunotherapy group and in only 8.48 patients treated with supportive care (P〈0.01). This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong the survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00368890
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients (1997)
    Springer
    Supportive care in cancer 5 (1997), S. 314-317 
    Details
    ISSN: 1433-7339
    Keywords: Key words 5-Fluorouracil-induced diarrhea ; Prognostic factors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality. No well-defined prognostic factors influencing 5FU-associated diarrhea have been identified, which means its occurrence is unforeseeable. The aim of this study was to check whether any characteristics related to patients or chemotherapy could allow the identification of subsets of patients at higher risk of developing diarrhea while receiving a regimen containing 5FU. A logistic regression analysis was performed with age, sex, site of primary tumor, presence of primary tumor, presence of colostomy, time since surgery, number of courses of chemotherapy, diarrhea in previous courses, season of treatment, and chemotherapeutic regimens used as model parameters to predict occurrence of diarrhea in 258 colorectal cancer patients receiving a 5FU-containing regimen. Presence of primary tumor (P=0.004), previous episodes of chemotherapy-related diarrhea (P=0.00005) and summer season (P=0.014) were found to be significant risk factors for developing diarrhea. The other variables examined, such as age, sex, chemotherapeutic regimen, site of primary tumor, presence of colostomy, and time since surgery, were not significantly correlated to diarrhea. Chemotherapeutic regimen was the only parameter that allowed prediction of the severity of diarrhea : 5FU/6S-leucovorin/interferon caused more severe diarrhea, followed by 5FU/leucovorin weekly. Although the analysis of these clinical features does not seem to allow the definition of a well-defined subset of colorectal cancer patients at higher risk of 5FU-induced diarrhea, it can be recommended that patients with primary tumor, or who have experienced diarrhea in earlier courses of chemotherapy or are receiving treatment in summer should be carefully monitored, especially in the first cycles.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s005200050079
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin (1996)
    Springer
    Supportive care in cancer 4 (1996), S. 313-316 
    Details
    ISSN: 1433-7339
    Keywords: Hypotension ; Immunotherapy ; Interleukin-2 ; Melatonin ; Nitric oxide ; Tumour necrosis factor α
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Hypotension is a frequent side-effect of cancer biotherapies with cytokines. Cytokine-induced hypotension would mainly depend on the stimulation of nitric oxide (NO) production, which represents the most effective endogenous vasodilator. Moreover, it has been proven that both biological activity and toxicity of cytokines are influenced by the psychoneuroendocrine system, in particular by the pineal hormone melatonin. To investigate the possible modulatory effect of melatonin on cytokine cardiovascular toxicity, we evaluated the influence of a concomitant melatonin administration on interleukin-2(IL-2)- and tumour-necrosis-factor-α(TNF)-induced hypotension in advanced cancer patients. The study included 116 patients with advanced solid tumour, for whom no effective standard anticancer therapy was available, who underwent cancer biotherapy with IL-2 (3 × 106 IU/day s.c. every day, 6 days/week for 4 weeks) or with TNF (0.75 mg/day i.v. for 5 days) as compassionate treatment for their disease. Patients were randomized to be treated with or without a concomitant melatonin administration (40 mg/day orally in the evening, starting 7 days prior to cytokine injection). The occurrence of hypotension was significantly less frequent in patients concomitantly treated by melatonin than in those who received the cytokine alone, during either IL-2 or TNF immunotherapy (IL-2: 11/45 versus 2/46,P〈0.05; TNF: 10/23 versus 1/12,P〈0.01). This study shows that melatonin may prevent hypotension occurring during cancer immunotherapy with IL-2 or TNF. Since the pineal hormone has appeared to inhibit the activity of NO synthase from the endothelial cells, we suggest that melatonin may prevent cytokine-induced hypotension by inhibiting NO production, which plays an essential role in inducing hypotension during IL-2 and TNF biotherapies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01358887
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...